Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
BCRX Quote, Financials, Valuation and Earnings
Last price:
$7.45
Seasonality move
:
6.23%
Day range:
$7.31 - $7.50
52-week range:
$6.00 - $11.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.68x
P/B ratio:
--
Volume:
2.6M
Avg. volume:
4.6M
1-year change:
-20.66%
Market cap:
$1.8B
Revenue:
$450.7M
EPS (TTM):
-$0.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$151.3M | $0.07 | 4.53% | 109900% | $21.20 |
|
BSEM
BioStem Technologies, Inc.
|
$55.2M | $0.02 | -37.86% | -100% | $25.5000 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$81M | -$0.18 | 63.91% | -57.98% | $9.11 |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$32.3M | -$0.53 | -- | -54.03% | $34.00 |
|
PKTX
Protokinetix, Inc.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$7.45 | $21.20 | $1.8B | -- | $0.00 | 0% | 2.68x |
|
BSEM
BioStem Technologies, Inc.
|
$6.0540 | $25.5000 | $101.5M | 7.11x | $0.00 | 0% | 0.57x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.87 | $9.11 | $1.1B | -- | $0.00 | 0% | 3.80x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$15.83 | $34.00 | $800.1M | -- | $0.00 | 0% | 54.92x |
|
PKTX
Protokinetix, Inc.
|
$0.0078 | -- | $3.1M | 23.85x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.28 | $5.50 | $37.8M | -- | $0.00 | 0% | 4.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
231.39% | 0.299 | 42.75% | 1.60x |
|
BSEM
BioStem Technologies, Inc.
|
6.34% | 0.058 | 4.31% | 3.87x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.707 | 6.28% | 2.92x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
94.33% | -2.502 | 45.9% | 6.99x |
|
PKTX
Protokinetix, Inc.
|
-- | -0.614 | -- | 0.00x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$156.9M | $29.6M | -2.54% | -- | 18.57% | $39.8M |
|
BSEM
BioStem Technologies, Inc.
|
$9.2M | $1.4M | 44.01% | 48.25% | 13.83% | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$12.5M | -$46.1M | -97.51% | -243.25% | -336.33% | -$54.8M |
|
PKTX
Protokinetix, Inc.
|
-$12.6K | -$84.9K | -111.59% | -111.59% | -- | -$9.5K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
BioCryst Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns BCRX or BSEM?
BioStem Technologies, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of 7.27%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat BioStem Technologies, Inc.'s return on equity of 48.25%.
Company Gross Margin Earnings Per Share Invested Capital BCRXBioCryst Pharmaceuticals, Inc.98.42% $0.06 $295.2M BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M -
What do Analysts Say About BCRX or BSEM?
BioCryst Pharmaceuticals, Inc. has a consensus price target of $21.20, signalling upside risk potential of 184.56%. On the other hand BioStem Technologies, Inc. has an analysts' consensus of $25.5000 which suggests that it could grow by 321.21%. Given that BioStem Technologies, Inc. has higher upside potential than BioCryst Pharmaceuticals, Inc., analysts believe BioStem Technologies, Inc. is more attractive than BioCryst Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCRXBioCryst Pharmaceuticals, Inc.7 0 0 BSEMBioStem Technologies, Inc.0 0 0 -
Is BCRX or BSEM More Risky?
BioCryst Pharmaceuticals, Inc. has a beta of 0.831, which suggesting that the stock is 16.851% less volatile than S&P 500. In comparison BioStem Technologies, Inc. has a beta of -0.090, suggesting its less volatile than the S&P 500 by 108.955%.
-
Which is a Better Dividend Stock BCRX or BSEM?
BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioStem Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioStem Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCRX or BSEM?
BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than BioStem Technologies, Inc. quarterly revenues of $10.5M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than BioStem Technologies, Inc.'s net income of $761.1K. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioStem Technologies, Inc.'s PE ratio is 7.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.68x versus 0.57x for BioStem Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCRXBioCryst Pharmaceuticals, Inc.2.68x -- $159.4M $12.9M BSEMBioStem Technologies, Inc.0.57x 7.11x $10.5M $761.1K
-
Which has Higher Returns BCRX or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -135.28%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital BCRXBioCryst Pharmaceuticals, Inc.98.42% $0.06 $295.2M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About BCRX or IOVA?
BioCryst Pharmaceuticals, Inc. has a consensus price target of $21.20, signalling upside risk potential of 184.56%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 217.46%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than BioCryst Pharmaceuticals, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than BioCryst Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCRXBioCryst Pharmaceuticals, Inc.7 0 0 IOVAIovance Biotherapeutics, Inc.6 4 0 -
Is BCRX or IOVA More Risky?
BioCryst Pharmaceuticals, Inc. has a beta of 0.831, which suggesting that the stock is 16.851% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.
-
Which is a Better Dividend Stock BCRX or IOVA?
BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCRX or IOVA?
BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.68x versus 3.80x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCRXBioCryst Pharmaceuticals, Inc.2.68x -- $159.4M $12.9M IOVAIovance Biotherapeutics, Inc.3.80x -- $67.5M -$91.3M
-
Which has Higher Returns BCRX or KALV?
KalVista Pharmaceuticals, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -361.39%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.
Company Gross Margin Earnings Per Share Invested Capital BCRXBioCryst Pharmaceuticals, Inc.98.42% $0.06 $295.2M KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M -
What do Analysts Say About BCRX or KALV?
BioCryst Pharmaceuticals, Inc. has a consensus price target of $21.20, signalling upside risk potential of 184.56%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 114.78%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than KalVista Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCRXBioCryst Pharmaceuticals, Inc.7 0 0 KALVKalVista Pharmaceuticals, Inc.7 0 0 -
Is BCRX or KALV More Risky?
BioCryst Pharmaceuticals, Inc. has a beta of 0.831, which suggesting that the stock is 16.851% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.191, suggesting its less volatile than the S&P 500 by 119.067%.
-
Which is a Better Dividend Stock BCRX or KALV?
BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCRX or KALV?
BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.68x versus 54.92x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCRXBioCryst Pharmaceuticals, Inc.2.68x -- $159.4M $12.9M KALVKalVista Pharmaceuticals, Inc.54.92x -- $13.7M -$49.5M
-
Which has Higher Returns BCRX or PKTX?
Protokinetix, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of --. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Protokinetix, Inc.'s return on equity of -111.59%.
Company Gross Margin Earnings Per Share Invested Capital BCRXBioCryst Pharmaceuticals, Inc.98.42% $0.06 $295.2M PKTXProtokinetix, Inc.-- -$0.00 $250.4K -
What do Analysts Say About BCRX or PKTX?
BioCryst Pharmaceuticals, Inc. has a consensus price target of $21.20, signalling upside risk potential of 184.56%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Protokinetix, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Protokinetix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCRXBioCryst Pharmaceuticals, Inc.7 0 0 PKTXProtokinetix, Inc.0 0 0 -
Is BCRX or PKTX More Risky?
BioCryst Pharmaceuticals, Inc. has a beta of 0.831, which suggesting that the stock is 16.851% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.569%.
-
Which is a Better Dividend Stock BCRX or PKTX?
BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCRX or PKTX?
BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than Protokinetix, Inc. quarterly revenues of --. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Protokinetix, Inc.'s net income of -$84.9K. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.68x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCRXBioCryst Pharmaceuticals, Inc.2.68x -- $159.4M $12.9M PKTXProtokinetix, Inc.-- 23.85x -- -$84.9K
-
Which has Higher Returns BCRX or PSTV?
Plus Therapeutics, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -316.61%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCRXBioCryst Pharmaceuticals, Inc.98.42% $0.06 $295.2M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About BCRX or PSTV?
BioCryst Pharmaceuticals, Inc. has a consensus price target of $21.20, signalling upside risk potential of 184.56%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than BioCryst Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than BioCryst Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCRXBioCryst Pharmaceuticals, Inc.7 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is BCRX or PSTV More Risky?
BioCryst Pharmaceuticals, Inc. has a beta of 0.831, which suggesting that the stock is 16.851% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock BCRX or PSTV?
BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCRX or PSTV?
BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.68x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCRXBioCryst Pharmaceuticals, Inc.2.68x -- $159.4M $12.9M PSTVPlus Therapeutics, Inc.4.41x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 23
RingCentral, Inc. [RNG] is down 8.48% over the past day.
Sell
9
FROG alert for Feb 23
JFrog Ltd. [FROG] is down 4.21% over the past day.
Buy
72
SNSE alert for Feb 23
Sensei Biotherapeutics, Inc. [SNSE] is down 6.51% over the past day.
